NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative
Halozyme Therapeutics (HALO) opened 2026 with Q1 revenue of US$376.7 million and basic EPS of US$1.27, against a backdrop where trailing 12 month revenue sits at about US$1.5 billion and EPS at US$2.94. Over recent quarters, the company has seen revenue move from US$298.0 million in Q4 2024 to US$264.9 million in Q1 2025, then to US$325.7 million in Q2 2025, US$354.3 million in Q3 2025, US$451.8 million in Q4 2025, before the latest US$376.7 million print. Quarterly basic EPS has ranged from...